Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Cialis annual sales?

See the DrugPatentWatch profile for Cialis

Cialis, a medication for erectile dysfunction and benign prostatic hyperplasia, generated approximately $1.9 billion in annual sales in 2022 [1][2]. Eli Lilly and Company is the manufacturer of Cialis [3].

How Does Cialis Revenue Break Down?


The $1.9 billion in annual sales for Cialis in 2022 reflects global revenue for the drug [1][2]. Eli Lilly's financial reports detail its performance in key markets [1].

When Does Cialis Lose Patent Protection?


The primary patents for Cialis have expired in major markets, including the United States and Europe, allowing for the introduction of generic versions [4][5]. In the U.S., patent protection for Cialis expired around 2017-2018, and in Europe, it expired in late 2017 [4][5]. This patent expiry has led to increased competition from generic manufacturers.

What is the Impact of Generic Competition on Cialis Sales?


The introduction of generic versions of tadalafil, the active ingredient in Cialis, has significantly impacted branded Cialis sales. As generic alternatives become available, they offer lower price points, often leading patients and healthcare providers to switch from the branded product. This shift is a common trend following patent expiry for widely used medications [4][5].

How Much Do Generic Cialis Pills Cost?


The cost of generic tadalafil varies depending on the pharmacy, dosage, and insurance coverage. However, generic versions are generally substantially less expensive than branded Cialis. For example, a prescription for 28 generic tadalafil 5 mg tablets could range from approximately $40 to $100 or more without insurance, whereas branded Cialis could cost significantly higher [6].

Who are the Competitors to Cialis?


Cialis competes with other medications for erectile dysfunction, including Viagra (sildenafil) and Levitra (vardenafil). It also faces competition from newer treatments and medical devices available for erectile dysfunction. For benign prostatic hyperplasia, it competes with other pharmaceutical treatments.

What are the Side Effects of Cialis?


Common side effects of Cialis include headache, indigestion, back pain, muscle aches, flushing, and nasal congestion [7]. Less common but more serious side effects can occur, and patients should consult their healthcare provider if they experience any concerning symptoms [7].

How Does Cialis Work?


Cialis works by increasing blood flow to the penis by relaxing the muscles in the blood vessels. This increased blood flow can help a man achieve and maintain an erection when sexually stimulated. For the treatment of benign prostatic hyperplasia, tadalafil relaxes smooth muscle in the prostate and bladder, improving urinary flow [7].

Sources:
[1] https://investor.lilly.com/news-releases/news-release-details/lilly-reports-fourth-quarter-and-full-year-2022-results
[2] https://www.drugpatentwatch.com/blog/cialis-sales-and-revenue
[3] https://www.drugpatentwatch.com/blog/cialis-patent-and-exclusivity
[4] https://www.drugpatentwatch.com/blog/cialis-patent-expiry-timeline
[5] https://www.drugpatentwatch.com/blog/tadalafil-generic-launch-dates
[6] https://www.drugpatentwatch.com/blog/cialis-cost-and-alternatives
[7] https://www.drugpatentwatch.com/blog/cialis-side-effects-and-uses



Other Questions About Cialis :

cialis 2.5 cost Cialis and avodart? Cialis free trial? Cialis timeline? Can i take cialis with blood pressure medication? Does cialis work faster than levitra? Cialis generic costs?

AI-Drug Label Prescribing Information Alignment Report

35
35%
Grade D

Poor

Not Aligned

Patient Risk: High

Summary

Most non-label business/competition/cost claims cannot be verified against the provided FDA label. However, the set of evaluated claims includes at least one direct, high-severity label contradiction regarding concomitant nitrate use, plus additional safety-related contradictions not supported by the label text provided.


Category Scores

Indication
100
Excellent
Contraindications
0
Dangerous mismatch
Contraindications
0
Dangerous mismatch

Accurate Statements

Cialis is a medication for erectile dysfunction.
Indications section 1.1: "CIALIS® is indicated for the treatment of erectile dysfunction (ED)."
Cialis is a medication for benign prostatic hyperplasia.
Indications section 1.2: "CIALIS is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH)."
Cialis is a medication for ED and benign prostatic hyperplasia (ED/BPH).
Indications section 1.3: "CIALIS is indicated for the treatment of ED and the signs and symptoms of BPH (ED/BPH)."

Unsupported Statements

Cialis generated approximately $1.9 billion in annual sales in 2022.
No sales/revenue or market-performance information is provided in the supplied label excerpts.
Eli Lilly and Company is the manufacturer of Cialis.
No manufacturer information is provided in the supplied label excerpts.
The $1.9 billion in annual sales for Cialis in 2022 reflects global revenue for the drug.
No revenue definition/scope information is provided in the supplied label excerpts.
Primary patents for Cialis have expired in major markets including the United States and Europe.
No patent-expiration or generic-entry information is provided in the supplied label excerpts.
Patent expiration in the United States and Europe allows for the introduction of generic versions of Cialis.
No patent/generic-availability statements are provided in the supplied label excerpts.
In the United States, patent protection for Cialis expired around 2017-2018.
No patent-expiration timeline is provided in the supplied label excerpts.
In Europe, patent protection for Cialis expired in late 2017.
No patent-expiration timeline is provided in the supplied label excerpts.
Patent expiry has led to increased competition from generic manufacturers for Cialis.
No market-competition impact statements are provided in the supplied label excerpts.
The introduction of generic versions of tadalafil has significantly impacted branded Cialis sales.
No branded/generic sales impact statements are provided in the supplied label excerpts.
Generic tadalafil offers lower price points compared with branded Cialis.
No pricing information is provided in the supplied label excerpts.
As generic alternatives become available, patients and healthcare providers often switch from branded Cialis to generic versions.
No prescribing/switching behavior information is provided in the supplied label excerpts.
Generic tadalafil 5 mg tablets cost approximately $40 to $100 or more for 28 tablets without insurance.
No cost/pricing information is provided in the supplied label excerpts.
Branded Cialis costs significantly higher than generic tadalafil.
No cost/pricing information is provided in the supplied label excerpts.
Cialis competes with Viagra (sildenafil) for erectile dysfunction.
No competitive/pharmacoeconomic comparisons are provided in the supplied label excerpts.
Cialis competes with Levitra (vardenafil) for erectile dysfunction.
No competitive/pharmacoeconomic comparisons are provided in the supplied label excerpts.
Cialis competes with newer treatments and medical devices for erectile dysfunction.
No competitive/pharmacoeconomic comparisons are provided in the supplied label excerpts.
Cialis competes with other pharmaceutical treatments for benign prostatic hyperplasia.
No competitive/pharmacoeconomic comparisons are provided in the supplied label excerpts.
Common side effects of Cialis include headache.
The provided label excerpts do not list adverse reactions/side effects.
Common side effects of Cialis include indigestion.
The provided label excerpts do not list adverse reactions/side effects.
Common side effects of Cialis include back pain.
The provided label excerpts include back pain only in the context of renal impairment (8.7) and do not establish it as a 'common side effect.'
Common side effects of Cialis include muscle aches.
The provided label excerpts do not list adverse reactions/side effects.
Common side effects of Cialis include flushing.
The provided label excerpts do not list adverse reactions/side effects.
Common side effects of Cialis include nasal congestion.
The provided label excerpts do not list adverse reactions/side effects.
Less common but more serious side effects can occur with Cialis.
The provided label excerpts do not categorize 'less common' vs 'more serious' side effects or specify this wording.
Cialis works by increasing blood flow to the penis by relaxing muscles in the blood vessels.
The provided mechanism-of-action excerpt states tadalafil inhibits PDE5 and enhances cGMP; it does not describe the mechanism as 'relaxing muscles in the blood vessels' or 'increasing blood flow to the penis' in that phrasing.
The increased blood flow from Cialis can help a man achieve and maintain an erection when sexually stimulated.
The label excerpt supports that sexual stimulation is required and tadalafil enhances erectile function via PDE5 inhibition; it does not specifically use the 'increased blood flow' phrasing.
For treatment of benign prostatic hyperplasia, tadalafil relaxes smooth muscle in the prostate and bladder.
The provided label excerpt states the mechanism for reducing BPH symptoms 'has not been established' (12.1); it does not support this specific mechanism.
For treatment of benign prostatic hyperplasia, tadalafil improves urinary flow.
The provided label excerpts discuss IPSS improvement in clinical studies but do not state 'improves urinary flow.'

Contradictions

High

AI Statement
Cialis can be used with nitrates (any form of organic nitrate).

Label Reference
Contraindications 4.1

Moderate

AI Statement
Cialis may be taken with other PDE5 inhibitors (e.g., ADCIRCA) as part of therapy.

Label Reference
Warnings/Precautions 5.11


Important Omissions

No label-supported contraindication/warning context provided for medication interactions (e.g., nitrates, GC stimulators) or safety management despite multiple claims focusing on side effects and mechanisms.
Importance: Moderate

Safety Assessment

Potential Patient Risk: High
The claim set includes high-severity contraindication contradiction (nitrate coadministration) relative to the provided label excerpts; additionally, there are other safety-implicating contradictions regarding PDE5 inhibitor combinations.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Medium

Recommendation

Not Aligned

Primary Issue
Contains direct, label-contradicting safety/interaction statements involving contraindicated nitrate use and prohibited PDE5 inhibitor combinations.

Suggested Improvement
Remove or revise any statements that conflict with label contraindications/interaction restrictions (Sections 4.1 and 5.11 in the provided excerpts) and avoid unlabelled mechanism/side-effect/price/market-claims not supported by the supplied USPI text.

Drug Brand Mention Assessment

Branding Score
55
Visibility
56
Mentioned
Ranking
#1
Sentiment
50
Recommendation Status
mentioned only
Brand Perception
Best Known For

a medication for erectile dysfunction and benign prostatic hyperplasia


Core Claims
  • Cialis is a medication for erectile dysfunction and benign prostatic hyperplasia.
  • Cialis generated approximately $1.9 billion in annual sales in 2022.
  • Cialis patents have expired in major markets, allowing generic versions.
  • Generic tadalafil alternatives offer lower price points and can reduce branded sales.
  • Generic versions are generally substantially less expensive than branded Cialis.
Differentiators
  • Mentioned as having patent expiry that enabled generic competition.
  • Positioned in ED as competing with sildenafil and vardenafil.
  • Includes BPH context (tadalafil relaxes smooth muscle in prostate and bladder).

Pricing Perception: Mid Range
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Pfizer 14%
50 #6 No
Bayer 14%
50 #7 No